Antimalarial Drugs Market to Reach $2.6 Billion by 2035

Antimalarial drugs market was valued at $1.5 billion in 2025 and is projected to reach $2.6 billion by 2035, expanding at a CAGR of 5.3% during the forecast period (2026–2035). The market growth is primarily driven by the persistent global burden of malaria and increasing efforts toward disease elimination across endemic regions. According to the World Health Organization (WHO), global malaria funding reached approximately $4.0 billion in 2023, reflecting continued international commitment toward malaria control and elimination. However, this remains significantly below the estimated $7.8 billion required annually by 2025 to stay on track with global eradication targets. This widening funding gap is driving governments and international organizations to increase investments in cost-effective and scalable antimalarial drug procurement, thereby boosting market demand.

Browse the full report description of “Antimalarial Drugs Market Size, Share & Trends Analysis Report, By Drug Type (Artemisinin-based Combination Therapies (ACTs), Quinine & Related Alkaloids, Chloroquine & Derivatives, Mefloquine, Primaquine & Analogues, Atovaquone-Proguanil, Others), By Drug Class (Schizonticides, Gametocytocidal Agents, Prophylactic Agents), By Route of Administration (Oral Dosage Forms, Injectable / Intravenous Formulations, Others), By Application (Treatment of Malaria, Prophylaxis, Public Health & Control Programs, Clinical Trials & R&D), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Government / NGO Procurement), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/antimalarial-drugs-market

Additionally, large-scale public health procurement programs supported by organizations such as the Global Fund to Fight AIDS, Tuberculosis and Malaria play a crucial role in sustaining drug demand. The Global Fund reported that it accounted for approximately 62% of all international financing for malaria programs in 2023, highlighting its dominant role in drug purchasing and distribution. This increasing financial commitment is accelerating the adoption of affordable generic therapies and Artemisinin-based Combination Therapies (ACTs) across endemic regions. Governments are prioritizing bulk procurement strategies to ensure an uninterrupted drug supply, particularly in Africa and Southeast Asia. As a result, pharmaceutical manufacturers are expanding production capacities and strengthening supply chains to meet large-volume tenders, thereby driving sustained growth in the global antimalarial drugs market.

Competitive Landscape

Key companies operating in the global antimalarial drugs market include Cipla Limited, GlaxoSmithKline plc, Ipca Laboratories Limited, Novartis AG, and Sanofi S.A., among others. These companies are actively engaged in the research, development, manufacturing, and commercialization of antimalarial drugs, including Artemisinin-based Combination Therapies (ACTs), chloroquine derivatives, and other combination therapies.

They focus on improving drug efficacy, affordability, and accessibility, particularly in malaria-endemic regions across Africa and the Asia-Pacific. Strategic priorities include expansion of generic drug production, development of next-generation therapies to address drug resistance, and participation in global public health procurement programs supported by organizations such as the WHO and international funding agencies. Additionally, these players are strengthening their manufacturing capabilities, supply chain networks, and partnerships with governments and NGOs to ensure large-scale distribution and availability of life-saving antimalarial treatments.

• In November 2025, Medicines for Malaria Venture and Shaperon Inc. announced a collaboration to develop next-generation nanobody-based antimalarial therapies. These novel biologics aim to provide cost-effective and highly targeted treatment options with improved efficacy against resistant malaria strains. This partnership highlights ongoing innovation in biologics and advanced therapeutic approaches within the antimalarial drugs market.

• In April 2025, Fosun Pharma announced the expansion of its antimalarial portfolio and large-scale distribution initiative, including the donation of 900,000 WHO-prequalified artemisinin-based treatments manufactured by Guilin Pharma. The company also highlighted continued innovation in antimalarial drug development across prevention, treatment, and severe malaria management. This initiative supports global access while reinforcing the company’s role in advancing antimalarial drug innovation and supply.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Drug Type
  • By Drug Class
  • By Route of Administration
  • By Application
  • By Distribution Channels

Competitive Landscape – Cipla Limited, GlaxoSmithKline plc, Ipca Laboratories Limited, Novartis AG, and Sanofi S.A., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antimalarial Drugs Market Report Segment

By Drug Type

• Artemisinin-based Combination Therapies (ACTs)
• Quinine & Related Alkaloids
• Chloroquine & Derivatives
• Mefloquine, Primaquine & Analogues
• Atovaquone-Proguanil
• Others

By Drug Class

• Schizonticides
• Gametocytocidal Agents
• Prophylactic Agents

By Route of Administration

• Oral Dosage Forms (tablets, suspensions)
• Injectable / Intravenous Formulations
• Others

By Application

• Treatment of Malaria (Uncomplicated & Severe)
• Prophylaxis / Prevention
• Public Health & Control Programs
• Clinical Trials & R&D

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Government / NGO Procurement

Global Antimalarial Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/antimalarial-drugs-market